Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years

INTRODUCTION: Solanezumab is an anti-amyloid monoclonal antibody in clinical testing for treatment of Alzheimer's disease (AD). Its mechanism suggests the possibility of slowing the progression of AD. METHODS: A possible disease-modifying effect of solanezumab was assessed using a new statistic...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Alzheimers Dement (N Y)
Auteurs principaux: Liu-Seifert, Hong, Siemers, Eric, Holdridge, Karen C., Andersen, Scott W., Lipkovich, Ilya, Carlson, Christopher, Sethuraman, Gopalan, Hoog, Sharon, Hayduk, Roza, Doody, Rachelle, Aisen, Paul
Format: Artigo
Langue:Inglês
Publié: Elsevier 2015
Sujets:
Featured Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5975050/
https://ncbi.nlm.nih.gov/pubmed/29854931
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trci.2015.06.006
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires